Intended for healthcare professionals


Angiotensin converting enzyme inhibitors and lung cancer

BMJ 2018; 363 doi: (Published 24 October 2018) Cite this as: BMJ 2018;363:k4337

Linked research

Angiotensin converting enzyme inhibitors and risk of lung cancer

  1. Deirdre Cronin-Fenton, associate professor
  1. Department of Clinical Epidemiology, Aarhus University, Aarhus, Denmark
  1. dc{at}

Any extra risk must be balanced against the mortality benefits of ACEI use

Angiotensin converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers are indicated for the treatment of hypertension, heart disease, renal insufficiency, and chronic kidney disease. ACEIs decrease the production of angiotensin II, whereas angiotensin receptor blockers selectively block its binding to angiotensin receptors.1 These drugs target the renin angiotensin aldosterone system, which may play a role in cancer development.23

In a linked paper, Hicks and colleagues (doi:10.1136/bmj.k4209) use registry data from the UK Clinical Practice Research Datalink (CPRD) to investigate the association of antihypertensive drugs with the risk of lung cancer.4 Their study population included 992 061 people, newly treated with antihypertensive drugs between 1995 and 2015, with follow-up until end of December 2016. Their findings indicate an increased risk of lung cancer associated with the use of ACEIs compared with angiotensin receptor blockers; with the highest risk associated with more than 10 years of ACEI use. The authors propose …

View Full Text

Log in

Log in through your institution


* For online subscription